AP NEWS

cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada

August 29, 2018

MONT-SAINT-GUIBERT, Belgium & DURHAM, NC--(BUSINESS WIRE)--Aug 29, 2018--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that Health Canada has confirmed a cGMP compliance status for the company’s production facility in Durham, North Carolina. The Durham facility will be focused on achieving the goals of Promethera’s current strategic focus, developing and producing the starting material of HepaStem as a treatment for chronic liver disorders such as Non-alcoholic steatohepatitis (NASH) and Acute-on-chronic liver failure (ACLF). As part of this strategy, the company has decided on a full out-licensing of the Heparesc program to a commercial partner, and hence cancelled its New Drug Submission (NDS) before a final decision was reached by Health Canada in order to keep full negotiation flexibility with a future partner.

“The confirmation of our Durham factory’s cGMP compliance status brings us a step closer to commercial capabilities for the production of our HepaStem treatment,” says John Tchelingerian, PhD, President & CEO of Promethera Biosciences SA. “HepaStem’s multiple mechanisms of action could be a potential alternative to reverse the NASH disease process forming a possible solution for the damage inflicted by advanced NASH or other chronic liver diseases that can lead to ACLF. With our new focus, we decided the time was right to bring in a commercial partner that would carry the Heparesc technology across the regulatory finish line.”

“Our experienced manufacturing and quality teams in the US continue to work in line with very high-quality standards, as evident in our cGMP status confirmation, helping the site continue to play an important role in the overall group structure,” said Mark Johnston, Managing Director, Promethera Biosciences LLC.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc®, Hepabridge® are all registered trademarks of the PROMETHERA group.

LinkedIn:https://www.linkedin.com/company/promethera-biosciences

Twitter:https://twitter.com/Promethera

View source version on businesswire.com:https://www.businesswire.com/news/home/20180829005229/en/

CONTACT: Promethera Biosciences SA

Alexandra Schiettekatte

Alexandra.schiettekatte@promethera.com

Web:www.promethera.com

or

For media:

MacDougall Communications

Mario Brkulj or Shai Biran, Ph.D.

+49 89 2420 9345

or +1 781-235-3060

promethera@macbiocom.com

KEYWORD: UNITED STATES BELGIUM EUROPE NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Promethera Biosciences

Copyright Business Wire 2018.

PUB: 08/29/2018 04:00 AM/DISC: 08/29/2018 04:00 AM

http://www.businesswire.com/news/home/20180829005229/en

AP RADIO
Update hourly